TB-500: What It Is, Explained Plainly

TB-500 is a synthetic peptide that mirrors part of thymosin beta-4, a protein your body already makes. It has drawn attention in research and recovery circles, but standalone TB-500 is not something telos rx compounds on its own.

What TB-500 actually is

TB-500 is the common name for a synthetic version of a short segment of thymosin beta-4. Thymosin beta-4 is a small protein found naturally throughout human and animal tissue. It plays a role in how cells move and organize themselves. Researchers have spent years trying to isolate which fragment of it might be responsible for specific effects.

The name TB-500 is a research shorthand rather than a formal pharmaceutical designation. It typically refers to a 43-amino-acid sequence, described as the active core of thymosin beta-4. It is produced synthetically rather than extracted from animal or human tissue. Synthetic production gives researchers a consistent, reproducible peptide to study, which is part of why it became a common research tool.

Most of what is publicly known about TB-500 comes from laboratory and animal research rather than large human trials. It is frequently discussed alongside BPC-157, another peptide studied for related biological processes. The two are sometimes examined together in early research settings, which is one reason they are often mentioned in the same breath online.

Where telos rx stands on TB-500 today

telos rx does not currently offer standalone TB-500 for compounding. The FDA classified TB-500 as a Category 2 bulk substance in late 2023. That classification restricts partner compounding pharmacies from preparing or dispensing it as its own product, even with a prescription. It is a regulatory fact, not a judgment on the underlying research.

What telos rx does offer is a distinct BPC-157 plus TB-500 combination protocol. It is reviewed and structured separately from standalone TB-500. You can read more about telos rx's current status on TB-500 on the BPC-157 + TB-500 combination page. That page, and this article, describe the combination product as it exists today. Neither is a promise about future availability of TB-500 alone.

Why the distinction between standalone and combination matters

It is easy to assume that if a clinic offers a combination product, the individual components must also be available separately. That is not how compounding regulation works. Category 2 status applies specifically to TB-500 as a standalone bulk substance. Whether a specific combination formulation has been reviewed is a separate regulatory question entirely.

This is a common source of confusion for people researching peptides online. Forum posts and marketing pages do not always distinguish between the two. If a source implies you can order plain TB-500 through a licensed telehealth pathway without qualification, treat that claim with skepticism. Ask the pharmacy directly how the substance is classified.

How TB-500 differs from thymosin beta-4 itself

Thymosin beta-4 is the full-length, naturally occurring protein. TB-500 is a synthetic fragment intended to reproduce part of its activity in a smaller, more stable molecule. The two terms get used interchangeably in casual discussion, but they are not identical products. Regulatory status can differ depending on exactly what is being compounded.

This distinction matters when you are trying to verify a source or read a safety data sheet. A vial labeled thymosin beta-4 and a vial labeled TB-500 are not necessarily the same formulation, concentration, or purity. Neither should be assumed to be reviewed or dispensed the way a prescription medication typically is.

How this fits with what telos rx already offers

The combination protocol pairs TB-500 with compounded BPC-157. telos rx offers standalone BPC-157 for patients who are specifically interested in that peptide alone. Some patients researching recovery-focused peptides also ask about sermorelin, a growth-hormone-releasing peptide available today, as a different approach to a related goal.

Comparing these pages side by side is a useful way to understand what telos rx does and does not currently offer. Each page is kept current as the program evolves, so it is worth checking back rather than relying on a single reading.

What this means if you are researching TB-500

If your interest in TB-500 is about tissue repair, recovery, or general research curiosity, it helps to separate three questions. What is the peptide, what does current research say about it, and what is legally available to you through a licensed provider today. Those three answers are not the same thing. Conflating them is where most misinformation online starts.

telos rx's current, honest position is that TB-500 is not offered as a standalone compounded product. A separately reviewed combination with BPC-157 is what is available. If you are weighing whether that combination protocol fits your goals, a conversation with a licensed provider is the right next step, rather than sourcing the peptide independently.

How this classification came about

The FDA periodically reviews bulk substances nominated for compounding pharmacies to use. That review considers available safety data, manufacturing information, and other factors before a substance is placed into a category. TB-500 was reviewed through this process and placed into Category 2 in late 2023.

Category 2 is not the most restrictive designation the FDA uses, but it is restrictive enough that compounding pharmacies generally will not prepare a Category 2 substance as a standalone product. Pharmacies that continue to operate within current guidance, as telos rx's partners do, follow that restriction.

This kind of review happens across many bulk substances, not just TB-500. It reflects an ongoing regulatory process rather than a one-time, permanent judgment. Substances can, in principle, be reconsidered as more information becomes available, though telos rx does not treat that as something to expect on any particular timeline.

What responsible research looks like right now

If you want to keep learning while TB-500's standalone status remains restricted, read primary research rather than secondhand claims. Peer-reviewed studies, even preclinical ones, describe their methods and limitations directly. Marketing copy usually does not.

It also helps to separate three types of sources. There are peer-reviewed studies, which describe what was actually tested. There are regulatory pages, which describe what is currently permitted. There are commercial sources, which sometimes blur the two together to sound more authoritative than they are.

Treating those three categories differently, and giving the most weight to the first two, is a reasonable way to stay informed without being misled by outdated or exaggerated claims about availability.

It is also worth checking dates. A study, a regulatory page, or a product listing published years ago may not reflect TB-500's current classification. Confirming when a source was last updated takes a moment and can save you from acting on information that no longer applies. The same habit is worth applying to any peptide you research, not just this one.

Where to read more, from primary sources

For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.

Frequently Asked Questions

Is TB-500 the same as thymosin beta-4?

Not exactly. Thymosin beta-4 is the full-length natural protein, while TB-500 refers to a synthetic fragment built to reproduce part of its activity. The two names are often used loosely as if interchangeable, but they can differ in formulation and regulatory treatment.

Does telos rx sell TB-500 on its own?

No. telos rx does not currently offer standalone TB-500 for compounding because the FDA classified it as a Category 2 bulk substance in late 2023. telos rx does offer a separately reviewed BPC-157 plus TB-500 combination protocol.

Why is TB-500 restricted but the combination protocol is not?

Category 2 status applies to TB-500 as a standalone bulk substance. The BPC-157 plus TB-500 combination is a distinct, separately reviewed formulation, which is a different regulatory question from selling TB-500 by itself.

Is this a temporary situation?

There is no confirmed timeline for standalone TB-500 becoming available, and telos rx does not speculate about one. Regulatory classifications can be revisited over time, but there is currently no scheduled date for any change, so it is best not to plan around one.

Where can I read telos rx's official position on TB-500?

The BPC-157 plus TB-500 combination page describes what telos rx currently offers and does not offer regarding this peptide. It is the most current source for availability questions.

What should I do if I am specifically interested in TB-500 research?

Speak with a licensed provider about what is actually available and appropriate for you. A telos rx provider can discuss the BPC-157 plus TB-500 combination protocol if that fits what you are looking for. They can also explain how it differs from standalone TB-500 in plain terms.

telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Questions about the BPC-157 + TB-500 combination protocol? Message the telos rx care team or read more on the BPC-157 + TB-500 combination page.